A bid to boost access to Novartis’ drugs in India is putting hundreds of jobs on the chopping block.
Novartis India has forged an exclusive sales and distribution pact with Dr. Reddy’s Laboratories centered on certain established meds, including the pain-relief drug Voveran and Methergine, which is used to treat severe bleeding from the uterus after childbirth.
The pact is meant to broaden access to the meds beyond their current geographies, which Novartis and Dr. Reddy’s will accomplish “by significantly extending the reach of healthcare professionals through an expanded field force,” Novartis said. The deal will fuse Novartis India’s manufacturing and development know-how with Dr. Reddy’s sales and distribution muscle, the company said.
Novartis India plans to cut 400 jobs with the move. The company says it understands “the implications of this difficult decision,” so it’s offering employees a severance package and outplacement services.
Novartis employs more than 10,000 full-time staffers in India, the company said. Since January 2020, the company has hired more than 1,600 employees worldwide. Novartis’ Indian outfits plan to continue this hiring push in 2022, the company noted.
Meanwhile, Novartis is investing to upgrade its R&D and manufacturing footprint in the country. Over the past five years, it has spent more than $300 million on an Indian R&D support center, for instance.
Elsewhere in the country, the company is building out a $49 million manufacturing plant at Kalwe, which will manufacture oral cancer meds for the global market.
The Dr. Reddy’s news comes as Novartis conducts a strategic review of its generic unit, Sandoz. Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Sandoz, Bloomberg has said, citing people close to the matter. Novartis says it will provide an update on its plan for the generics outfit by the end of the year.
by Fraiser Kansteiner
Source: fiercepharma.com
Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.
The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.
A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.
